Advertisement

Hepatology International

, Volume 13, Issue 1, pp 84–90 | Cite as

Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis

  • Umair IqbalEmail author
  • Brittany B. Dennis
  • Andrew A. Li
  • George Cholankeril
  • Donghee Kim
  • Muhammad Ali Khan
  • Aijaz Ahmed
Original Article

Abstract

Background and aims

While the association between platelet activation and hepatic fibrosis has been previously demonstrated in animal studies; the utility of anti-platelet agents in reversing the progression of hepatic fibrosis requires further review. Utilizing systematic review methods, we provide to our knowledge the first meta-analysis combining evidence from all studies aimed to establish the effect of anti-platelet agents in the prevention of hepatic fibrosis.

Methods

We searched Medline, EMBASE and PubMed databases from inception to October 2018 to identify all studies aimed at evaluating the role of anti-platelet agents in the prevention of hepatic fibrosis. The primary outcome was hepatic fibrosis. The initial title, abstract, and full-text screening were performed in duplicate. Risk of bias was evaluated using the Newcastle–Ottawa Scale. A fixed-effect generic inverse variance method was used to create a pooled estimate of the odds of hepatic fibrosis in patients with anti-platelet agents versus without anti-platelet agents.

Results

Among the 2310 unique articles identified during the title screening, 4 studies with a combined population of 3141 patients were deemed eligible for inclusion into the meta-analysis establishing the effect of anti-platelet agents on hepatic fibrosis. One study failed to report their findings in the entire cohort, electing to instead summarize the effects of anti-platelets within subgroups categorized by fibrotic risk factors. Use of anti-platelets was associated with 32% decreased odds of hepatic fibrosis, (adjusted pooled OR 0.68; CI 0.56–0.82, p ≤ 0.0001). The statistical heterogeneity among the studies was insignificant.

Conclusion

Use of anti-platelet agents is associated with the decreased odds of hepatic fibrosis. Due to limited evidence, future high-quality randomized controlled trials with larger comparative samples are required to further delineate the potential beneficial effects of these drugs in preventing hepatic fibrosis.

Keywords

Hepatic fibrosis Aspirin Anti-platelets Systematic review 

Notes

Author contributions

UI: study design, literature searching, data abstraction and manuscript writing, statistical analysis. BBD: manuscript writing and drafting the tables. AAL: study design, manuscript writing. GC: study design and manuscript writing. DK: study design, literature review and manuscript writing and reviewing. MAK: study design, literature review and manuscript writing and reviewing. AA: study design, literature search and review. Manuscript writing and finalizing.

Funding

There were no funding sources for this study.

Compliance with ethical standards

Conflict of interest

Umair Iqbal, Brittany B. Dennis, Andrew A. Li, George Cholankeril, Donghee Kim, Muhammad Ali Khan and Aijaz Ahmed declare no conflict of interest, including financial and/or material support for the preparation of this manuscript.

References

  1. 1.
    Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med 2016;25(375):767–777CrossRefGoogle Scholar
  2. 2.
    Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther Adv Gastroenterol 2011;4(6):391–417CrossRefGoogle Scholar
  3. 3.
    Friedman SL, Sheppard D, Duffield JS, et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013;5(167):167sr1CrossRefGoogle Scholar
  4. 4.
    Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012;109(32):E2165–E2172CrossRefGoogle Scholar
  5. 5.
    Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 2014;147(6):1378–1392CrossRefGoogle Scholar
  6. 6.
    Denda A, Tang Q, Endoh T, et al. Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, l-Amino acid-defined diet in rats. Carcinogenesis 1994;15(6):1279–1283CrossRefGoogle Scholar
  7. 7.
    Fujita K, Nozaki Y, Wada K, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008;57(11):1583–1591CrossRefGoogle Scholar
  8. 8.
    Chávez E, Castro-Sánchez L, Shibayama M, et al. Effects of acetyl salycilic acid and ibuprofen in chronic liver damage induced by CCl4. J Appl Toxicol 2012;32(1):51–59CrossRefGoogle Scholar
  9. 9.
    Wanless IR, Belgiorno J, Huet PM. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 1996;24(4):855–864CrossRefGoogle Scholar
  10. 10.
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264–269, W64CrossRefGoogle Scholar
  11. 11.
    Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–560CrossRefGoogle Scholar
  12. 12.
    Jiang ZG, Feldbrügge L, Tapper EB, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2016;43(6):734–743CrossRefGoogle Scholar
  13. 13.
    Poujol-Robert A, Boëlle P-Y, Conti F, et al. Aspirin may reduce liver fibrosis progression: evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. Clin Res Hepatol Gastroenterol 2014;38(5):570–576CrossRefGoogle Scholar
  14. 14.
    Singh A, Gosai F, Lopez R, et al. Regular aspirin use is not protective against advanced fibrosis in type-2 diabetics with biopsy-proven nonalcoholic fatty liver disease. J Hepatol 2018;1(68):S582–S583CrossRefGoogle Scholar
  15. 15.
    Schwarzkopf K, Bojunga J, Rüschenbaum S. Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease. Hepatol Commun 2018.  https://doi.org/10.1002/hep4.1254.Google Scholar
  16. 16.
    Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010;103(1):71–82CrossRefGoogle Scholar
  17. 17.
    Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009;145(4):362–371CrossRefGoogle Scholar
  18. 18.
    Segal R, Lubart E, Leibovitz A, Berkovitch M, Habot B, Yaron M, et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med 2003;115(6):462–466CrossRefGoogle Scholar
  19. 19.
    Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011;9(9):762.e6–768.e6CrossRefGoogle Scholar
  20. 20.
    Patel SS, Guzman LA, Lin F-P, Pence T, Reichman T, John B, et al. Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. Liver Transpl 2018;24(7):872–880CrossRefGoogle Scholar
  21. 21.
    Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol 2017;112(10):1495–505CrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2018

Authors and Affiliations

  1. 1.Department of MedicineGeisinger Commonwealth School of MedicineDanvilleUSA
  2. 2.St. George’s Hospital Medical SchoolUniversity of LondonLondonUK
  3. 3.Department of MedicineStanford University School of MedicineStanfordUSA
  4. 4.Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA
  5. 5.Division of Gastroenterology and HepatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations